Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to ...

Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a ...

Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare ...

Sanofi said. Write to Adria Calatayud at [email protected] and to Helena Smolak at Helena Smolak at [email protected] We sell different types of products and services to both investment ...

Sanofi SNY has entered into exclusive negotiations ... Opella’s current portfolio of products includes brands such as Allegra, Doliprane and Dulcolax. The above transaction will classify Opella ...

In Monday's announcement, Sanofi CEO Paul Hudson appeared to try to allay concerns. He said: "We share the love and emotional attachment to Opella’s brands, hence our decision to remain vested ...

The new entity will operate under the brand of Orano Med, a subsidiary of Orano Group. Sanofi already has a relationship ... Maryland, provides products and services to the nuclear industry.

Building on the expertise and radioligand pipeline of Orano Med, Sanofi and Orano will invest in a new entity, operating under the Orano Med brand ... high value-added products and services ...

Building on the expertise and radioligand pipeline of Orano Med, Sanofi and Orano will invest in a new entity, operating under the Orano Med brand ... high value-added products and services ...